Clopidogrel rebound may be possible in patients with ACS

High, Katherine A.; Pepine, Carl J.
March 2008
Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p45
The article discusses research on the adverse effects that can be experienced by patients with acute coronary syndrome who are treated with clopidogrel after discontinuing the use of the drug. It references a study published in a 2008 issue of the "Journal of the American Medical Association." It found that acute myocardial infarction (MI) occurred in 7.9% of the patients examined.


Related Articles

  • Levothyroxine sodium.  // Reactions Weekly;6/23/2007, Issue 1157, p17 

    The article describes the medical case of a 67-year-old man with autoimmune hyperthyroidism who developed myocardial infarction during treatment with levothyroxine sodium. On the 80th day of levothyroxine treatment, the patient developed a persistent chest pain and presented to a hospital. He...

  • Adenosine.  // Reactions Weekly;9/27/2008, Issue 1221, p7 

    The article describes the case of eight patients who developed atrial fibrillation (AF) while undergoing adenosine stress myocardial perfusion imaging (MPI). One patient experienced nausea and abdominal discomfort during infusion while a second one experienced a myocardial infarction. A total of...

  • Reteplase.  // Reactions Weekly;10/13/2007, Issue 1173, p23 

    The article describes the case of a patient who developed retro-orbital hemorrhage during treatment with reteplase for an acute myocardial infarction. The patient presented with an acute ST-segment myocardial infarction and received reteplase. The symptoms associated with retro-orbital...

  • Immune globulin.  // Reactions Weekly;1/19/2008, Issue 1185, p19 

    The article presents a case study of a 65-year-old man with a history of coronary artery (CAD) who developed a myocardial infarction during treatment with immune globulin infusion for common variable immunodeficiency. While receiving immune globulin, he developed sudden onset of chest...

  • Nutritional supplement.  // Reactions Weekly;7/19/2008, Issue 1211, p25 

    The article describes the case of adverse drug effect of a nutritional supplement. It presents a 39-year-old male competitive bodybuilder who developed acute myocardial infarction, probably secondary to coronary spasms and thrombosis, while using a nutritional supplement, which included the...

  • Effect of PPIs on aspirin-treated patients with myocardial infarction.  // Australian Journal of Pharmacy;Nov2011, Vol. 92 Issue 1098, p91 

    The article discusses the effect of proton pump inhibitors (PPIs) on myocardial infarction (MI) patients treated with aspirin. As stated, PPIs are used to prevent peptic ulcers in aspirin-treated patients (ATPs). A study was carried out to analyze the effect of PPIs on adverse cardiovascular...

  • β-Blockers in coronary artery disease management. Boudonas, G. E. // Hippokratia;Oct-Dec2010, Vol. 14 Issue 4, p231 

    Beta-blockers are a multiform group of drugs with multiple applications in the treatment of patients with cardiovascular disease. Their adverse actions are multiple and relate mainly to the β-adrenergic receptor blockade. They are used to treat all forms of coronary disease, but especially in...

  • Current management of patients with ST elevation myocardial infarction in Metropolitan Beijing, China. Shou -Yan Zhang; Da -Yi Hu; Yi -Hong Sun; Jin- Gang Yang // Clinical & Investigative Medicine;Aug2008, Vol. 31 Issue 4, pE189 

    Purpose: To assess clinical practices and in-hospital outcomes of patients with ST elevation myocardial infarction (STEMI) in Beijing, China. Methods: This study was a prospective multicentre registry study in Metropolitan Beijing, China. Demographics, delay time, management strategy and...

  • Myocardial Infarction in a Patient with a Hageman (Factor XII) Defect. Glueck, Helen I.; Roehll Jr., Walter // Annals of Internal Medicine;Feb66, Vol. 64 Issue 2, p390 

    Presents a case report of the occurrence of myocardial infarction in a patient with an absolute deficiency of the Hageman factor (XII). Information on the patient; Results of the examination of the patient; Clotting studies.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics